Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00108836 |
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
Condition | Intervention | Phase |
---|---|---|
Anxiety Disorders |
Drug: XBD173 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder |
Estimated Enrollment: | 400 |
Study Start Date: | March 2005 |
Study Completion Date: | May 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
For detailed information on eligibility, please contact the study center nearest to you (see below), or call 1-862-778-8300, or visit the following website:
www.novartisclinicaltrials.com
United States, California | |
Investigational Site | |
Anaheim, California, United States, 92801 | |
Investigational Site | |
San Diego, California, United States, 92108 | |
Investigational Site | |
Los Angeles, California, United States, 90024 | |
Investigational Site | |
Newport Beach, California, United States, 92660 | |
Investigational Site | |
Redlands, California, United States, 92374 | |
United States, Florida | |
Investigational Site | |
West Palm Beach, Florida, United States, 33407 | |
Investigational Site | |
St. Petersburg, Florida, United States, 33702 | |
Investigational Site | |
Ft. Meyers, Florida, United States, 33712 | |
United States, Georgia | |
Investigational Site | |
Atlanta, Georgia, United States, 30308 | |
United States, Illinois | |
Investigational Site | |
Hoffman Estates, Illinois, United States, 60194 | |
Investigational Site | |
Oak Brook, Illinois, United States, 60523 | |
United States, Kansas | |
Investigational Site | |
Overland Park, Kansas, United States, 66211 | |
United States, Ohio | |
Investigational Site | |
Dayton, Ohio, United States, 45408 | |
United States, Oregon | |
Investigational Site | |
Portland, Oregon, United States, 97239 | |
United States, Tennessee | |
Investigational Site | |
Memphis, Tennessee, United States, 38119 | |
Investigational Site | |
Madison, Tennessee, United States, 37115 | |
Canada, Alberta | |
Investigational Site | |
Edmonton, Alberta, Canada, T6G 2C8 | |
Canada, British Columbia | |
Investigational Site | |
Kelowna, British Columbia, Canada, V1Y 2H4 | |
Canada, Ontario | |
Investigational Site | |
Ottawa, Ontario, Canada, 7K4 | |
Investigational Site | |
Toronto, Ontario, Canada, 1R8 | |
Investigational Site | |
Hamilton, Ontario, Canada, 3Z5 | |
Canada, Quebec | |
Investigational Site | |
Sherbrooke, Quebec, Canada, 4J6 | |
Investigational Site | |
Montreal, Quebec, Canada, 2N6 |
Study ID Numbers: | CXBD173A2204 |
Study First Received: | April 19, 2005 |
Last Updated: | November 28, 2007 |
ClinicalTrials.gov Identifier: | NCT00108836 |
Health Authority: | United States: Food and Drug Administration |
GAD Anxiety XBD173 Generalized Anxiety Disorder |
Anxiety Disorders Mental Disorders |
Pathologic Processes Disease |